Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine.

@article{Silverman2006TransfusionII,
  title={Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine.},
  author={Lewis R. Silverman and Bercedis L. Peterson and James F. Holland and Richard M. Stone and Bayard L. Powell and Richard A. Larson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18\_suppl},
  pages={6576}
}
  • L. SilvermanB. Peterson R. Larson
  • Published 20 June 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
6576 Background: Patients (pts) receiving red blood cell (RBC) transfusions are exposed to various side-effects such as intolerance reactions, iron overload, and alloimmunization risks. Reduction in RBC transfusions plus improvement in quality of life was demonstrated in pts with MDS treated with azacitidine in the phase 3 randomized study (9221) conducted by the CALGB (JCO 2002;20:2429). Azacitidine also demonstrated beneficial effects on platelets and neutrophils. To further explore… 
1 Citations